The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting growing confidence in the biotech pipeline, HSBC has upgraded Gilead Sciences (GILD) from Hold to Buy. The bank significantly raised its price target for the stock from $133 to $155. Analysts noted that the market currently holds an overly pessimistic view on the long-acting HIV therapy sector, suggesting that the intrinsic value of the company's specialized portfolio is being underestimated.
This optimism is bolstered by the potential of pipeline assets such as Yeztugo and the oncology drug Trodelvy, positioning Gilead strongly against biotech peers. Compared to competitors like GSK, which also focuses on HIV treatments, market experts suggest Gilead's expansion into oncology provides a strategic revenue cushion. Per market data, such upgrades from major institutions often signal a shift in sentiment toward large-cap healthcare value stocks.
As of the close on July 2, 2026, GILD was priced at $131.27, indicating significant upside potential relative to HSBC's new target. Traders are watching support levels near the recent daily low of $126.46 for entry opportunities. With no major sector-specific catalysts in the immediate economic calendar, investor focus will likely remain on clinical trial updates and regulatory milestones for the HIV pipeline.